 |
|
Postlicensure Safety Surveillance for Varicella Vaccine
Robert P. Wise, MD, MPH;
Marcel E. Salive, MD, MPH;
M. Miles Braun, MD, MPH;
Gina Terracciano Mootrey, DO, MPH;
Jane F. Seward, MBBS, MPH;
Lisa G. Rider, MD;
Philip R. Krause, MD
JAMA. 2000;284:1271-1279.
Context Since its licensure in 1995, the extensive use of varicella vaccine and close surveillance of the associated anecdotal reports of suspected adverse effects provide the opportunity to detect potential risks not observed before licensure because of the relatively small sample size and other limitations of clinical trials.
Objectives To detect potential hazards, including rare events, associated with varicella vaccine, and to assess case reports for clinical and epidemiological implications.
Design and Setting Postlicensure case-series study of suspected vaccine adverse events reported to the US Vaccine Adverse Event Reporting System (VAERS) from March 17, 1995, through July 25, 1998.
Main Outcome Measures Numbers of reported adverse events, proportions, and reporting rates (reports per 100,000 doses distributed).
Results VAERS received 6574 case reports of adverse events in recipients of varicella vaccine, a rate of 67.5 reports per 100,000 doses sold. Approximately 4% of reports described serious adverse events, including 14 deaths. The most frequently reported adverse events were rashes, possible vaccine failures, and injection site reactions. Misinterpretation of varicella serology after vaccination appeared to account for 17% of reports of possible vaccine failures. Among 251 patients with herpes zoster, 14 had the vaccine strain of varicella zoster virus (VZV), while 12 had the wild-type virus. None of 30 anaphylaxis cases was fatal. An immunodeficient patient with pneumonia had the vaccine strain of VZV in a lung biopsy. Pregnant women occasionally received varicella vaccine through confusion with varicella zoster immunoglobulin. Although the role of varicella vaccine remained unproven in most serious adverse event reports, there were a few positive rechallenge reports and consistency of many cases with syndromes recognized as complications of natural varicella.
Conclusion Most of the reported adverse events associated with varicella vaccine are minor, and serious risks appear to be rare. We could not confirm a vaccine etiology for most of the reported serious events; several will require further study to clarify whether varicella vaccine plays a role. Education is needed to ensure appropriate use of varicella serologic assays and to eliminate confusion between varicella vaccine and varicella zoster immunoglobulin.
Author Affiliations: Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research (Drs Wise, Salive, and Braun) and Laboratories of Molecular and Developmental Immunology, Division of Monoclonal Antibodies, Office of Therapeutics Research and Review (Dr Rider) and DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review (Dr Krause), Food and Drug Administration, Rockville, Md; and Branches of Vaccine Safety and Development (Dr Mootrey) and Child Vaccine Preventable Diseases (Dr Seward), Division of Epidemiology and Surveillance, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Ga.
RELATED ARTICLE
September 13, 2000
JAMA. 2000;284(10):1317-1318.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Severe Varicella Caused by Varicella-Vaccine Strain in a Child With Significant T-Cell Dysfunction
Jean-Philippe et al.
Pediatrics 2007;120:e1345-e1349.
ABSTRACT
| FULL TEXT
Varicella-zoster vaccine virus: Evolution in action
Cohen
Proc. Natl. Acad. Sci. USA 2007;104:7-8.
FULL TEXT
Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety
O'Neill and Isenberg
Lupus 2006;15:778-783.
ABSTRACT
Preventing Varicella-Zoster Disease
Hambleton and Gershon
Clin. Microbiol. Rev. 2005;18:70-80.
ABSTRACT
| FULL TEXT
The Varicella-Zoster Virus Open Reading Frame 63 Latency-Associated Protein Is Critical for Establishment of Latency
Cohen et al.
J. Virol. 2004;78:11833-11840.
ABSTRACT
| FULL TEXT
Postlicensure Safety Surveillance for 7-Valent Pneumococcal Conjugate Vaccine
Wise et al.
JAMA 2004;292:1702-1710.
ABSTRACT
| FULL TEXT
Varicella
English
Pediatr. Rev. 2003;24:372-379.
FULL TEXT
Risk of Anaphylaxis After Vaccination of Children and Adolescents
Bohlke et al.
Pediatrics 2003;112:815-820.
ABSTRACT
| FULL TEXT
Safety of Live Viral Vaccines in Patients With Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome)
Perez et al.
Pediatrics 2003;112:e325-325.
ABSTRACT
| FULL TEXT
Varicella vaccination in England and Wales: cost-utility analysis
Brisson and Edmunds
Arch. Dis. Child. 2003;88:862-869.
ABSTRACT
| FULL TEXT
Varicella Disease After Introduction of Varicella Vaccine in the United States, 1995-2000
Seward et al.
JAMA 2002;287:606-611.
ABSTRACT
| FULL TEXT
Active Immunization in the United States: Developments over the Past Decade
Dennehy
Clin. Microbiol. Rev. 2001;14:872-908.
ABSTRACT
| FULL TEXT
Current topic: Varicella vaccination{---}a critical review of the evidence
Skull and Wang
Arch. Dis. Child. 2001;85:83-90.
FULL TEXT
Disseminated Vaccine Strain Varicella as the Acquired Immunodeficiency Syndrome-Defining Illness in a Previously Undiagnosed Child
Kramer et al.
Pediatrics 2001;108
:e39-e39.
ABSTRACT
| FULL TEXT
Chickenpox vaccination, not chickenpox, should be routine for Canadian children
Law
CMAJ 2001;164:1454-1455.
FULL TEXT
Adverse Effects Minimal with Varicella Vaccine
JWatch Infect. Diseases 2000;2000:7-7.
FULL TEXT
|
